Related Experiment Videos
Chelation therapy and cardiac status in older patients with thalassemia major
1Pediatric Division of Hematology/Oncology, Columbia University, College of Physicians & Surgeons, New York, New York 10032.
Insights
Cardiac dysfunction is a major risk for patients with beta-thalassemia. While chelation therapy improved outcomes for most older patients, some still require new approaches for cardiac health.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Homozygous beta-thalassemia frequently leads to cardiac dysfunction and death.
- Iron overload from regular transfusions complicates management in these patients.
Observation:
- A study of 10 older beta-thalassemia patients (mean age 17.5) initiated chelation therapy 10 years post-transfusion.
- Two noncompliant patients with deferoxamine therapy died from cardiac failure; compliant patients showed reduced ferritin levels.
Findings:
- Despite improved iron levels, three compliant patients experienced worsening cardiac issues, with one responding to alternative chelation.
- Most older patients initiating chelation therapy later benefited from standard deferoxamine regimens.
Implications:
- Standard chelation may not suffice for all older beta-thalassemia patients with cardiac dysfunction.
- Novel therapeutic strategies are needed for select patients to improve cardiac outcomes.
Abstract:
Cardiac dysfunction is the most common cause of death in patients with homozygous beta-thalassemia. We studied a group of 10 older patients (mean age 17.5 years) with and without preexisting cardiac dysfunction who had begun chelation therapy on the average of 10 years after regular transfusions were initiated. Over the 4-year study period, two patients were noncompliant with deferoxamine therapy. Their clinical status and cardiac function deteriorated, and both died with evidence of arrhythmia and congestive heart failure. The remaining eight patients were compliant. Despite a drop in mean serum ferritin from 3,814 +/- 577 (SE) ng/ml to 1,056 +/- 146 ng/ml (p less than 0.01), two patients with preexisting cardiac problems and one patient without preexisting heart disease developed further abnormalities. Of the three patients whose status declined, one ultimately improved with alternative chelation therapy. These data suggest that for a few older patients, improvement or stabilization of cardiac status may not be achieved with improved compliance and reduced serum ferritin levels. For these patients, new approaches appear to be warranted. On the other hand, we have demonstrated that in most cases, older patients who began chelation therapy years after transfusions began have benefited from compliance with standard subcutaneous deferoxamine regimens.